REFERENCES
- Haimovich S. Profile of long-acting reversible contraception users in Europe. Eur J Contracept Reprod Health Care 2009;14:187–95.
- Graesslin O, Korver T. The contraceptive efficacy of Implanon®: A review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care 2008;13(Suppl. 1):4–12.
- Croxatto HB, Mäkäräinen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception 1998;58:91S–97S.
- Blumenthal PD, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability and clinical safety of Implanon®. Eur J Contracept Reprod Health Care 2008;13(Suppl. 1): 29–36.
- Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): Results from 11 international clinical trials. Fertil Steril 2009;91:1646–53.
- Laban M, AbdAlhamid M, Ibrahim EA, et al. Endometrial histopathology, ovarian changes and bleeding patterns among users of long-acting progestin-only contraceptives in Egypt. Eur J Contracept Reprod Health Care 2012;17:451–7.
- Jeffreys LA, Clark AL. A successful approach to long-acting contraceptive implants in primary care. Contraception 2012;85:381–3.
- Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon® on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008;13(Suppl. 1):13–28.
- Casey PM, Long ME, Marnach ML, et al. Association of body mass index with removal of etonogestrel subdermal implant. Contraception 2013; 87:370–4.
- Casey PM, Long ME, Marnach ML, Bury JE. Bleeding related to etonogestrel subdermal implant in a US population. Contraception 2011;83:426–30.
- Lakha F, Glasier AF. Continuation rates of Implanon® in the UK: Data from an observational study in a clinical setting. Contraception 2006;74:287–9.
- Riney S, O’Shea B, Forde A. Etonogestrel implant as a contraceptive choice: Patient acceptability and adverse effect profile in a general practice setting. Ir Med J 2009;102:24–5.
- Ezegwui HU, Ikeako LC, Ishiekwene CI, Oguanua TC. The discontinuation rate and reasons for discontinuation of Implanon at the family planning clinic of University of Nigeria Teaching Hospital (UNTH) Enugu, Nigeria. Niger J Med. 2011;20:448–50.
- Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception 2009;80:527–32.
- Short M, Dallay D, Omokanye S, et al. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: One-year results of an observational study. Eur J Contracept Reprod Health Care 2012; 17:79–88.
- Rubenstein J, Rubenstein P, Barter J, Pittrof R. Counselling styles and their effect on subdermal contraceptive implant continuation rates. Eur J Contracept Reprod Health Care 2011;16:225–8.
- Mansour D, Bahamondes L, Critchley H, et al. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception 2011;83:202–10.
- Weisberg E, Hickey M, Palmer D, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009;24:1852–61.
- Vitzthum VJ, Ringheim K. Hormonal contraception and physiology: A research-based theory of discontinuation due to side effects. Stud Fam Plann 2005;36: 13–32.
- Bitzer J, Gemzell-Danielsson K, Roumen F, et al. The CHOICE study: effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries. Eur J Contracept Reprod Health Care 2012;17:65–78.